<SEC-DOCUMENT>0001193125-23-253395.txt : 20231010
<SEC-HEADER>0001193125-23-253395.hdr.sgml : 20231010
<ACCEPTANCE-DATETIME>20231010150451
ACCESSION NUMBER:		0001193125-23-253395
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20231010
FILED AS OF DATE:		20231010
DATE AS OF CHANGE:		20231010

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		231317682

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d516963d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of October, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&nbsp;&#9745;&#8195;&#8195;&#8195;&#8195; Form
<FONT STYLE="white-space:nowrap">40-F&#8194;&nbsp;&#9744;</FONT> </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX and Nasdaq Trading Halt Extension </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October 10, 2023, Kazia Therapeutics Limited (the &#147;Company&#148;) requested an extension to the halt to the trading of the
Company&#146;s securities quoted on the Australian Securities Exchange (ASX) until October 11, 2023 in accordance with the Listing Rules of the ASX. The Company also requested an extension to the halt to the trading of the Company&#146;s American
Depositary Shares listed on the Nasdaq Capital Market until October 11, 2023 in accordance with the Nasdaq Listing Rules. The document is furnished herewith as Exhibit 99.1 to this report on Form 6-K. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d516963dex991.htm">ASX Announcement of Kazia Therapeutics Limited dated October&nbsp;10, 2023 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited</B> (Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Karen Krumeich</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Karen Krumeich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: October&nbsp;10, 2023</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d516963dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g516963img1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0c3b6c"><B>Market Announcement </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0c3b6c">10 October 2023 </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g516963imgn2.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0c3b6c">Kazia Therapeutics Limited (ASX: KZA) &#150; Suspension from Quotation </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#009fdf"><B>Description </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities
of Kazia Therapeutics Limited (&#145;KZA&#146;) will be suspended from quotation immediately under Listing Rule 17.2, at the request of KZA, pending the release of an announcement regarding the proposed trading solely on Nasdaq and proposed
delisting of KZA&#146;s securities from ASX. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#009fdf"><B>Issued by </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Alan Zhao </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adviser, Listings Compliance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT COLOR="#0c3b6c"><B>10&nbsp;October 2023</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT COLOR="#0c3b6c"><B>Market Announcement 1/1</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT COLOR="#0c3b6c">ASX Limited</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT COLOR="#0c3b6c">ASX Customer Service Centre 131 279 | asx.com.au</FONT></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g516963imgn3.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10 October 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ms Lisa
Bahn </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Adviser, Listings Compliance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX Limited, 20
Bridge Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SYDNEY NSW 2000 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REQUEST
FOR VOLUNTARY SUSPENSION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BY EMAIL:
<U>t</U><U>r</U><U>a</U><U>d</U><U>i</U><U>n</U><U>g</U><U>h</U><U>al</U><U>t</U><U>ss</U><U>y</U><U>dn</U><U>e</U><U>y@</U><U>as</U><U>x</U><U>.</U><U>c</U><U>o</U><U>m.au</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Lisa </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Limited- Request for Voluntary
Suspension </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (ASX : KZA) (<B>Kazia </B>or the <B>Company</B>) requests an voluntary suspension to the trading of the
Company&#146;s securities quoted on the Australian Securities Exchange (<B>ASX</B>) in accordance with the ASX Listing Rule 17.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with
Listing Rule 17.2, the Company provides the following information in relation to the request: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the voluntary suspension is requested pending an announcement by Kazia regarding the proposed trading solely on
Nasdaq and proposed delisting of the Company&#146;s securities from ASX (<B>Announcement</B>). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company requests that the voluntary suspension remains in place until the earlier of commencement of normal
trading on 11 October 2023, or when it makes the Announcement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company expects to make the Announcement to ASX before the commencement of normal trading on 11 October
2023. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company is not aware of any reason why the voluntary suspension should not be granted, or of any further
information necessary to inform the market about the voluntary suspension. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours faithfully </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Anna Sandham </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anna Sandham </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer.
Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase II study in glioblastoma reported promising signals of clinical activity in 2021, and a pivotal study in
glioblastoma, GBMAGILE, is ongoing, with final data expected in CY2023. Other clinical trials are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these having reported encouraging interim data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the FDA in
August 2020. Paxalisib was also awarded Fast Track Designation (FTD) in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare
Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumours (AT/RT) in June 2022 and July 2022, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to
be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A Phase I study commenced recruitment in November 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit
<U>w</U><U>ww</U><U>.ka</U><U>z</U><U>i</U><U>a</U><U>t</U><U>h</U><U>era</U><U>p</U><U>e</U><U>u</U><U>tics.c</U><U>o</U><U>m</U> or follow us on Twitter @KaziaTx. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain
forward-looking statements, which can generally be identified as such by the use of words such as &#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;future,&#148; &#147;forward,&#148; &#147;anticipate,&#148; or other similar words. Any
statement describing Kazia&#146;s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements
regarding: the timing for results and data related to Kazia&#146;s clinical and preclinical trials, and Kazia&#146;s strategy and plans with respect to its programs, including paxalisib and EVT801. Such statements are based on Kazia&#146;s current
expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking
statements, including risks and uncertainties: associated with clinical and preclinical trials and product development, related to regulatory approvals, related to Kazia&#146;s executive leadership changes, and related to the impact of global
economic conditions.. These and other risks and uncertainties are described more fully in Kazia&#146;s Annual Report, filed on form 20-F with the SEC, and in subsequent filings with the United States Securities and Exchange Commission. Kazia
undertakes no obligation to publicly update any <FONT STYLE="white-space:nowrap">forward-looking</FONT> statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place
undue reliance on these forward-looking statements, which apply only as of the date of this announcement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by
the Board of Directors. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g516963img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g516963img1.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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48NR>AJB:D 4 % !0 4 % !0!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g516963imgn2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g516963imgn2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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M>E_'+_H<I/\ P MO_C='_#TOXY?]#E)_X 6W_P ;K]6?^&/_ (5_]$]\'_\
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M-/\ H=S_ / JG_R1^4W_  ]+^.7_ $.4G_@!;?\ QNC_ (>E_'+_ *'*3_P
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M8_\ A7_T3WP?_P""N'_XFC_AC_X5_P#1/?!__@KA_P#B:/\ 7_AG_H61_P#
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MZ%D?_ :?^0?\0HXT_P"AW/\ \"J?_)'Y3?\ #TOXY?\ 0Y2?^ %M_P#&Z/\
MAZ7\<O\ H<I/_ "V_P#C=?JS_P ,?_"O_HGO@_\ \%</_P 31_PQ_P#"O_HG
MO@__ ,%</_Q-'^O_  S_ -"R/_@-/_(/^(4<:?\ 0[G_ .!5/_DC\IO^'I?Q
MR_Z'*3_P MO_ (W1_P /2_CE_P!#E)_X 6W_ ,;K]6?^&/\ X5_]$]\'_P#@
MKA_^)H_X8_\ A7_T3WP?_P""N'_XFC_7_AG_ *%D?_ :?^0?\0HXT_Z'<_\
MP*I_\D?E-_P]+^.7_0Y2?^ %M_\ &Z/^'I?QR_Z'*3_P MO_ (W7ZL_\,?\
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M.7_0Y2?^ %M_\;K]6?\ AC_X5_\ 1/?!_P#X*X?_ (FC_AC_ .%?_1/?!_\
MX*X?_B:/]?\ AG_H61_\!I_Y!_Q"CC3_ *'<_P#P*I_\D?E-_P /2_CE_P!#
ME)_X 6W_ ,;H_P"'I?QR_P"ARD_\ +;_ .-U^K/_  Q_\*_^B>^#_P#P5P__
M !-'_#'_ ,*_^B>^#_\ P5P__$T?Z_\ #/\ T+(_^ T_\@_XA1QI_P!#N?\
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M_C='_#TOXY?]#E)_X 6W_P ;K]6?^&/_ (5_]$]\'_\ @KA_^)H_X8_^%?\
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M7^&?_A/6W_Q%']OY3_T"+[HA_8N8_P#04_O9_/K_ ,/[OVKO^BL3?^"G3_\
MXS1_P_N_:N_Z*Q-_X*=/_P#C-?T%?\.U/V?/^B+_  S_ /">MO\ XBC_ (=J
M?L^?]$7^&?\ X3UM_P#$4?V_E/\ T"+[HA_8N8_]!3^]G\^O_#^[]J[_ **Q
M-_X*=/\ _C-'_#^[]J[_ **Q-_X*=/\ _C-?T%?\.U/V?/\ HB_PS_\ ">MO
M_B*/^':G[/G_ $1?X9_^$];?_$4?V_E/_0(ONB']BYC_ -!3^]G\^O\ P_N_
M:N_Z*Q-_X*=/_P#C-'_#^[]J[_HK$W_@IT__ .,U_05_P[4_9\_Z(O\ #/\
M\)ZV_P#B*/\ AVI^SY_T1?X9_P#A/6W_ ,11_;^4_P#0(ONB']BYC_T%/[V?
MSZ_\/[OVKO\ HK$W_@IT_P#^,T?\/[OVKO\ HK$W_@IT_P#^,U_05_P[4_9\
M_P"B+_#/_P )ZV_^(H_X=J?L^?\ 1%_AG_X3UM_\11_;^4_] B^Z(?V+F/\
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-A,1AXR6(J.=]O(__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g516963imgn3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g516963imgn3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MSI,_[M&?]V@!?S_.C\_SI,_[M&?]V@!?S_.C\_SI,_[M&?\ =H 7\_SH_/\
M.DS_ +M&?]V@!?S_ #H_/\Z3/^[1G_=H 7\_SH_/\Z3/^[1G_=H 7\_SH_/\
MZ3/^[1G_ ': %_/\Z/S_ #I,_P"[1G_=H 7\_P Z/S_.DS_NT9_W: %_/\Z/
MS_.DS_NT9_W: %_/\Z/S_.DS_NT9_P!V@!?S_.C\_P Z3/\ NT9_W: %_/\
M.C\_SI,_[M&?]V@!?S_.C\_SI,_[M&?]V@!?S_.C\_SI,_[M&?\ =H 7\_SH
M_/\ .DS_ +M&?]V@!?S_ #H_/\Z3/^[1G_=H 7\_SH_/\Z3/^[1G_=H 7\_S
MH_/\Z3/^[1G_ ': %_/\Z/S_ #I,_P"[1G_=H 7\_P Z/S_.DS_NT9_W: %_
M/\Z/S_.DS_NT9_W: %_/\Z/S_.DS_NT9_P!V@!?S_.C\_P Z3/\ NT9_W: %
M_/\ .C\_SI,_[M&?]V@!?S_.C\_SI,_[M&?]V@!?S_.C\_SI,_[M&?\ =H 7
M\_SH_/\ .DS_ +M&?]V@!?S_ #H_/\Z3/^[1G_=H 7\_SH_/\Z3/^[1G_=H
M7\_SH_/\Z3/^[1G_ ': %_/\Z/S_ #I,_P"[1G_=H 7\_P Z/S_.DS_NT9_W
M: %_/\Z/S_.DS_NT9_W: %_/\Z/S_.DS_NT9_P!V@!?S_.C\_P Z3/\ NT9_
MW: %_/\ .C\_SI,_[M&?]V@!?S_.C\_SI,_[M&?]V@!?S_.C\_SI,_[M&?\
M=H 7\_SH_/\ .DS_ +M&?]V@!?S_ #H_/\Z3/^[1G_=H 7\_SH_/\Z3/^[1G
M_=H 7\_SH_/\Z3/^[1G_ ': )]6_Y"=U_P!=7_\ 0A4'X_I4^K?\A.Z_ZZO_
M .A"H/\ OJL</_#7R_)%U?C?]=6'X_I1^/Z4?]]4?]]5L0'X_I1^/Z4?]]4?
M]]4 'X_I1^/Z4?\ ?5'_ 'U0 ?C^E'X_I1_WU1_WU0 ?C^E'X_I1_P!]4?\
M?5 !^/Z4?C^E'_?5'_?5 !^/Z4?C^E'_ 'U1_P!]4 'X_I1^/Z4?]]4?]]4
M'X_I1^/Z4?\ ?5'_ 'U0 ?C^E'X_I1_WU1_WU0 ?C^E'X_I1_P!]4?\ ?5 !
M^/Z4?C^E'_?5'_?5 !^/Z4?C^E'_ 'U1_P!]4 'X_I1^/Z4?]]4?]]4 'X_I
M1^/Z4?\ ?5'_ 'U0 ?C^E'X_I1_WU1_WU0 ?C^E'X_I1_P!]4?\ ?5 !^/Z4
M?C^E'_?5'_?5 !^/Z4?C^E'_ 'U1_P!]4 'X_I1^/Z4?]]4?]]4 'X_I1^/Z
M4?\ ?5'_ 'U0 ?C^E'X_I1_WU1_WU0 ?C^E'X_I1_P!]4?\ ?5 !^/Z4?C^E
M'_?5'_?5 !^/Z4?C^E'_ 'U1_P!]4 'X_I1^/Z4?]]4?]]4 'X_I1^/Z4?\
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MVXYXHYD [C_)HX_R::SX8J=J,-H/(^4\]5)RN05(SUITBM&6W;5."<-E=G'
M;Z\<@XHYD%F''^31Q_DTT@^8ZA9-P"D;HSQN( R,94YW=?[H]:<$;;G;^?(&
M2-N<#DL"/N],-GI1S(->H<?Y-''^336RH;Y3A-IW''S;MP ]B6 Z_P!X4X'
MYV_@<BJ ./\ )HX_R:,CVHR/:@ X_P FCC_)HR/:C(]J #C_ ":./\FC(]J,
MCVH ./\ )HX_R:,CVHR/:@ X_P FCC_)HR/:C(]J #C_ ":./\FC(]J,CVH
M./\ )HX_R:,CVHR/:@ X_P FCC_)HR/:C(]J #C_ ":./\FC(]J,CVH ./\
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M5?%T5Q>Z3=:U<N\MQ9O)'$2S$A PP#UJ_IG@/QA\?KO5O$99-3N/- N+B>;
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MKT>^C5K'XGG&5XKA7,(X;'?[/0@N5TY1:ESO6[T;U6K;=DCY;R:;.[11,_\
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M1.6C,2K@NIK'VTX:R5S6-&$G[KL?'AF17VEUW 9QN&0,9_ES1Y\?EAO,7:>
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MWYT8'M^= !@^_P"=&#[_ )T8'M^=&![?G0 8/O\ G1@^_P"=&![?G1@>WYT
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MBJ,#CKD^]?E:<,3TZ^M>KA:TJD+S@X^3/-KTXTY<L7S>:/U*_P"#7EO^+O\
MQ:_[ MA_Z/DKP/\ X+^C/_!3SQ=[:7IW_I.M:W_!#K]N[X<?L*_$;XA:E\1]
M2U+3;?Q)I]K;V;V6G2WH9XY79AB-25P".2,5Y5_P5C_:8\)_M>?MN^(/'/@F
MZNKSP[?V5G;P2W5L]K(SQPA7/EN PP>.1SUKBITY_7I3:=K;_<==2I'ZG&">
MM]CYP"LS*!N5B1@CD@]L?4X'MG-?MA_P;B?L?1_#/X :C\7=6LUCUKX@.;?2
MRZ_ZO2XB<,N>1YD@<9&=RQ*W1Z_%WPKI^EZMXITNUUJ^FTO1;J\ABU&]@@-Q
M+9VS2*)94C'WV1-S!>Y K]?/VO\ _@O)\+?"G[(O_"(_L\:EK%AXFMK>UTK2
M"VB2VL.B6<6%R#,%4E8T"*!G[P/8U691JS2I4T]=WY"R]TX2=6H]MEU/H'X<
M_L9?''P?_P %3/%7QPU/Q/X%N/ OB*T;1&T6*]N_M<&F1*!:C!MMGF*RB1AO
MP&DDY/4_-_\ P<K?L@7&M:1X9^-VAVBR-HZ?V%KNT$'RF8M;3-CH$D:1"3C&
M]:^(O^'S7[3.<M\5M9;C;Q!;CC! ./+^]W/.,X]Z^Y/A_P#\%J_@I^T5^P#)
M\.?CMJVN:?XNUO1)=#UNXM-#GNH[F0#;'?J8P5$C';,5&,2*^!C;GA6%Q-&I
M&K:_33L=?MZ%6$J:=KZZ]S\?1&(U55W%% "DC:2N."1V)&..U&#[_G2(/E^9
M@S=SMVY/TR<#\:7 ]OSKZ)'B!@^_YT8/O^=&![?G1@>WYT &#[_G1@^_YT8'
MM^=&![?G0!/JW_(3NO\ KJ__ *$*@Q_G%3ZM_P A.Z_ZZO\ ^A"H?SK&A_#7
MR_)%U?C?]=6)C_.*,?YQ2_G1^=;$:"8_SBD(8-N4[6Q@'&<9Z\4[\Z:TFP]&
M/L/O-]!ZU(M#33P'K0\$?\)+_9=]'X=COQIQU,(PMTN2H8)NX^8C!VYQ\OJ:
MW];_ &=O'?A;PKI6M7_A+6+/2M:BM#87+P!H[E+N-9+94QDJ)D92FX'(<@<D
M >]Z7X@^&*?LO+\,6\4ZE!XE?P<?$LD@L8/['_MR5TOU5;T7'G!TM$@MS$;?
M!DCD^8!\#I/&^O\ A.R^%OAN^C_X0G09;[2?AS"]_I_B%KK5_$,EAI6F0SV]
MY9/+*EO':-#*-T20@F ;A*2Q/&Z\^:R75G4L/"UV_P"NQ\F^+?A;XF\":GK=
MGK&A:EI%YX=U#^SM4CN8-CZ?=-N8)(6X+NP9L# XZ]ZL)\%/&%Y%HIA\,ZR%
M\59_L4M;,JZ@3'O7RRV"WR'<I)'RMD=<#W[]K+XI^&_BS\'/&&K6^I:;-XF_
MX2Y-&O8!<9?6;.U-P+&_&"ORBS:*U8#"D6438W.U8?Q&L?[?_9R\-:+<_$/P
M[JFN>(-:T6XL[Y=5:Y\V'^SEM%^W(P\RR_LT?Z/A2%90?EDVI(*5:;5W^O0E
MT87T_JYX_J/P6\76?Q!C\*S^'-6C\17&+F'3&@;SQ"ZF1)  >4:(E]V?N8)(
MJ!/A!XK,6ML/#FM!?#$A35PUFXDL& R5E[JPVL6"@$_,6 KVZ\\?Z1XT_:W^
M*5GIFLV>GZ;J7AF_\$^$[[4;W[+;FWM+2*RL=\I^5/,AM%RQ//F8SELCUOXA
M_%KX?^/X?&EO<7_A.]M=)FACU35Y-7GM[Z9XO"5CI[7-BB3*EXTFH64R$LDH
M9)=P!$A)F5:::5N@XT8--W/BWQ'\-?$'@KP[IFJ:MHNJ:;I>K1B6RNIX"D-V
MI!<%&Q@AE(96!PT95@3VW-.^"GQ L?$5MI=KX9\36NJ>(+&5X;9;:2.74+4*
M!( <_,L:A48$= N0":]&^..K06W[)&GZ?J'BO1?$&L:EJ^G:O'-8ZP;ZZUF$
M:6\"I<P/\UG]@'^B*J! YWDJR^7L]$\4>+M6^$WCGP+H<.K>!?&3KI.N3W&J
M:QXE6ZM?$&JZE#;&^>8P.KP19BM(HD=HS*8)9"8_-V)7MIVV)]C&^Y\RZG\'
M/%VC6&K37GA_58;?09VM-3=H"L=G(H0L&*GC:)$/&<*5[%<OB^"'BZY\#Q>)
MH_#>K2>'[R6)$U!+<-#/(\HMU0%1\I\S8H!4G)'K7U7KOC3X;Z+X<\>0Z7+X
M770?#"Z]#H\5EXIZRZGING!XX[*:%WO86O+>46\\=PNU8Y1*K8BV^$_#;QQ;
M_#+]G6UFCU&WDUCQ%XXL3+ ]PV+73]+5+@M+MRRPS75S 0R]["0;3C-$:LVK
MV[%2I06YQ^K_  &\<:%XXTOPO>^%-<A\1:P1]ATQK?-U>$L4"HG)&UE8;0,C
M!)R"#7*W,$EC=202(T,MN?)97!S"W.Y2N<[B002<#CI7VQX*^*GP_P#!'[8W
MP]\5>(+KP[X<\37%W<S7=QX1E;5-+MC)J<;6US*\EUNBE:&6X#,&X5(3Y?)
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L #<_[U&?]ZG44 -S_O49_P!ZG44 -S_O49_WJ=10 W/^]1G_ 'J=10!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
